Figure 4.
Patient survival according to the expression of S100A2 in patients with p53‐positive or p53‐negative tumors. (a) S100A2 positivity was not associated with prognosis of patients with p53‐positive tumors (P = 0.6517). (b) S100A2 positivity was significantly associated with favorable outcome in patients with p53‐negative tumors (P = 0.0448).